Cardiogen

Mechanism of Action

Cardiogen's proposed mechanism is the Khavinson short-peptide bioregulator framework applied to cardiac tissue. The three-stage model — absorption and distribution, nuclear import, sequence-selective chromatin modulation — has been detailed for the bioregulator family as a whole and is asserted without tissue-specific experimental validation for AEDR in cardiomyocytes.

Step 1 — Absorption and tissue distribution. At ~488 daltons (H-Ala-Glu-Asp-Arg-OH), Cardiogen is small, polar, and sufficiently flexible to cross phospholipid bilayers passively. Khavinson tritiated-peptide biodistribution work in rodents describes tissue uptake across heart, liver, brain, thymus, and kidney within minutes of intraperitoneal or oral administration (Khavinson et al., 2014). The radiolabel studies do not distinguish intact peptide from hydrolysis products, so claims about AEDR reaching cardiomyocyte nuclei intact rest on inference rather than direct structural confirmation.

Step 2 — Sarcolemmal passage and nuclear import. The proposed mechanism has AEDR diffusing through the cardiomyocyte sarcolemma, T-tubule membrane system, and nuclear envelope without receptor-mediated transport. Once inside the nucleus, AEDR is claimed to make sequence-selective contacts with exposed DNA regions and histone tails, particularly in chromatin regions carrying cardiac survival and regeneration genes. The molecular validation standards modern chromatin biology would apply — co-crystal structures, genome-wide ChIP-seq on tagged peptide, ATAC-seq changes in dose-matched controls, CUT&RUN profiling — have not been published in English-indexed literature for any Khavinson tetrapeptide, including AEDR.

Step 3 — Cardiomyocyte-specific transcriptional effects. Khavinson's group proposes that AEDR preferentially activates silenced chromatin regions carrying cardiac-survival genes: mitochondrial biogenesis (PGC-1α family), survival factors (BCL-2, Bax ratio), contractile proteins (myosin heavy chains), calcium-handling proteins (SERCA2a, ryanodine receptor), and anti-fibrotic programmes. Russian in vitro work on cultured cardiomyocytes describes morphological preservation and improved contractility markers after AEDR exposure in models of oxidative stress and ischaemic simulation (Chalisova et al., 2014). The data are consistent with "something is happening in cell culture" but do not establish a defined molecular mechanism.

Alternative conservative framing. A more parsimonious interpretation treats Cardiogen as an amino-acid source delivering alanine, glutamate, aspartate, and arginine in a rapidly hydrolysed short-peptide form. In that framing, biological effects could reflect: (a) substrate delivery for cardiomyocyte protein synthesis, (b) specific arginine-related effects on nitric oxide production and endothelial function (arginine is the substrate for nitric oxide synthase), (c) aspartate-mediated gluconeogenesis and Krebs cycle anaplerosis, or (d) non-specific stress-protective effects common to amino-acid mixtures. If this framing is correct, AEDR would not be unique — equivalent amino-acid provision by any means would produce similar effects.

Comparison to arginine-based cardiovascular therapies. Cardiogen contains arginine as one of four amino acids in the tetrapeptide. Arginine itself is a supplement with modest evidence for endothelial function in certain populations (erectile dysfunction, peripheral arterial disease). L-citrulline, which converts to arginine via the urea cycle, has somewhat better evidence and improved pharmacokinetic profile. ADMA/nitric-oxide pathway biology is well-established. If Cardiogen acted primarily as an arginine source, equivalent clinical effect could be obtained from L-citrulline 3–6 g daily at far lower cost and with better pharmacokinetic data. The Khavinson framework proposes mechanism beyond amino-acid delivery; the evidence for that additional mechanism is thin.

Receptor pharmacology. No G-protein-coupled receptor, nuclear receptor, or defined enzyme target has been identified for Cardiogen. It does not bind β1- or β2-adrenoceptors (the target of β-blockers), angiotensin II receptors (the target of ARBs), or aldosterone receptors (target of spironolactone/eplerenone). It does not inhibit ACE, renin, or neprilysin. The absence of a defined pharmacological target is the hallmark of the Khavinson framework and explains why Western cardiac pharmacology has not adopted the compound.

Relation to other Khavinson peptides. Cardiogen occupies the cardiac-specific niche within the Khavinson programme. Chelohart is the parallel polypeptide extract from bovine heart tissue, positioned as an undefined-mixture cardiac bioregulator. Cardiogen was synthesised as a defined chemical alternative intended to reproduce the extract's biological activity in pure form. Whether that strategy succeeds — whether AEDR reproduces Chelohart's effects, or whether either actually has the claimed biological action — is the open question that modern pharmacological methodology has not yet addressed.

Compared to evidence-graded cardiac mechanisms. β-blockers act through competitive β-adrenoceptor blockade with quantified kinetics and decades of RCT support. ACE inhibitors and ARBs modulate the renin-angiotensin-aldosterone system with mapped molecular mechanisms. Statins inhibit HMG-CoA reductase with structural biology-level understanding. SGLT2 inhibitors block renal glucose reabsorption through characterised transporters with heart-failure outcomes data. Cardiogen sits at a completely different level of mechanistic specification — hypothesis about chromatin, not measured pharmacological action.

Cardiogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St. Petersburg Institute of Bioregulation and Gerontology, positioned as a "myocardial bioregulator" intended to support cardiomyocyte function, vascular endothelium, and cardiac tissue resilience in age-related cardiovascular decline, post-infarction recovery, and chronic heart failure. It is usually described in Khavinson-family publications as the tetrapeptide Ala-Glu-Asp-Arg (AEDR), sometimes rendered H-Ala-Glu-Asp-Arg-OH or A-E-D-R, and sits alongside Pinealon, Thymogen, Vilon, Epitalon, Livagen, and Bronchogen within the Khavinson short-peptide bioregulator family. Cardiogen is the synthetic defined-sequence counterpart to a polypeptide product called Chelohart (or Korteksin for the brain-targeted version), which is prepared from bovine cardiac tissue extract — mirroring the extract-plus-defined-sequence pattern Khavinson's group applies across the bioregulator programme.

Outside Russia, Cardiogen is not registered as a drug, not reviewed by FDA, EMA, or PMDA, and not listed on WADA's Prohibited List — though the WADA S0 catch-all for "non-approved substances" arguably covers any unregistered peptide for competitive athletes. There are no phase II or phase III randomised trials indexed in PubMed or ClinicalTrials.gov, and Cardiogen does not appear in ACC/AHA, ESC, or NICE guidelines for ischaemic heart disease, heart failure, or cardiac aging. The published Russian work comprises in vitro cardiomyocyte culture experiments, small rodent studies of induced cardiac injury, and uncontrolled observational case series in elderly patients with chronic cardiovascular disease (Khavinson et al., 2011; Chalisova et al., 2014; Anisimov et al., 2010).

The central claim for Cardiogen is the standard Khavinson short-peptide model applied to cardiac tissue: passive membrane permeation through the cardiomyocyte sarcolemma, nuclear import, and sequence-selective chromatin modulation producing preferential up-regulation of cardiomyocyte-survival, mitochondrial-biogenesis, and regeneration programmes. Tissue-specific targeting toward the heart — rather than liver, brain, or thymus — is asserted but not supported by structural biology, modern biodistribution, or contemporary transcriptomic characterisation of cardiac tissue after AEDR exposure. The hypothesis is internally consistent within the Khavinson framework; it is substantially less validated than the pharmacology of even modestly-studied cardiac therapies.

BodyHackGuide covers Cardiogen because it is sold online in post-Soviet supplement channels (typically 20 mg oral capsules containing an undisclosed amount of actual peptide) and appears frequently in longevity-stack discussions framed as a cardiac-support bioregulator. We describe what is known, what is claimed, and what is missing — and we steer readers seeking evidence-graded cardiovascular protection toward interventions with overwhelming replication: blood-pressure control, LDL-cholesterol reduction via statins and PCSK9 inhibitors, SGLT2 inhibitors for heart failure and diabetic cardiomyopathy, GLP-1 agonists for cardiometabolic risk, anticoagulation where indicated, and aerobic exercise as the single most important lifestyle variable in cardiac aging. Cardiogen is a plausible hypothesis. It is not, in 2026, a cardiovascular therapy.

IUPAC Name

L-Alanyl-L-glutamyl-L-aspartyl-glycine

CAS Number

70381-80-5

Molecular Formula

Ala-Glu-Asp-Gly

Molecular Mass

402.37 g/mol

Unlock Dosing Protocols

Free account gets you:

• View beginner, intermediate & advanced protocols
• See weight-based dosing calculations
• Access cycle length & frequency data

2,800+ researchers already in

Unlock Research Data

Free account gets you:

• Browse PubMed study summaries
• See clinical trial phases & results
• Access mechanism of action details

2,800+ researchers already in

Interaction Matrix

Get Cardiogen Price Drop Alerts

Set a target price and we'll notify you when any vendor drops below it.

Related Compounds

Data Completeness

Research Credibility